Profile data is unavailable for this security.
About the company
Lyell Immunopharma, Inc. is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. The Company is engaged in enrolling a Phase I clinical trial evaluating a ROR1-targeted CAR T-cell therapy in patients with relapsed refractory triple-negative breast cancer and non-small cell lung cancer (NSCLC) and a second Phase I clinical trial evaluating reprogrammed tumor infiltrating lymphocytes (TIL) in patients with advanced melanoma, NSCLC and colorectal cancer. The technologies powering its product candidates are designed to address barriers that limit consistent and long-lasting responses to cell therapy for solid tumors: T-cell exhaustion and lack of durable stemness, which includes the ability to persist and self-renew to drive durable tumor cytotoxicity. The Company is applying its proprietary ex vivo genetic and epigenetic reprogramming technologies to address these barriers in order to develop medicines.
- Revenue in USD (TTM)130.00k
- Net income in USD-234.63m
- Incorporated2018
- Employees224.00
- LocationLyell Immunopharma Inc201 Haskins Way, Suite 301SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 695-0677
- Fax+1 (302) 531-3150
- Websitehttps://lyell.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compass Pathways PLC (ADR) | 0.00 | -118.46m | 582.96m | 186.00 | -- | 2.34 | -- | -- | -2.39 | -2.39 | 0.00 | 3.64 | 0.00 | -- | -- | 0.00 | -50.06 | -40.85 | -54.08 | -44.48 | -- | -- | -- | -- | -- | -- | 0.113 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
| Wave Life Sciences Ltd | 113.31m | -57.51m | 585.74m | 266.00 | -- | 14.40 | -- | 5.17 | -0.5397 | -0.5397 | 1.07 | 0.3987 | 0.5378 | -- | -- | 425,958.70 | -27.30 | -56.98 | -70.41 | -102.38 | -- | -- | -50.76 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
| Prime Medicine Inc | 0.00 | -198.13m | 591.30m | 234.00 | -- | 3.61 | -- | -- | -2.17 | -2.17 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -71.51 | -- | -84.13 | -- | -- | -- | -- | -- | -- | -85.97 | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
| Allogene Therapeutics Inc | 95.00k | -327.27m | 593.51m | 232.00 | -- | 1.16 | -- | 6,247.50 | -2.09 | -2.09 | 0.0006 | 3.04 | 0.0001 | -- | -- | 409.48 | -44.70 | -28.46 | -47.65 | -30.21 | -- | -- | -344,489.50 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
| Mineralys Therapeutics Inc | 0.00 | -71.90m | 595.57m | 28.00 | -- | 2.05 | -- | -- | -1.79 | -1.79 | 0.00 | 5.86 | 0.00 | -- | -- | 0.00 | -39.28 | -- | -41.38 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
| Northwest Biotherapeutics Inc | 1.93m | -64.37m | 596.29m | 25.00 | -- | -- | -- | 308.64 | -0.0573 | -0.0573 | 0.0017 | -0.04 | 0.0653 | -- | -- | 77,280.00 | -211.53 | -381.58 | -- | -- | -- | -- | -3,240.11 | -6,479.25 | -- | -- | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
| Fate Therapeutics Inc | 63.53m | -160.93m | 596.42m | 181.00 | -- | 1.41 | -- | 9.39 | -1.63 | -1.63 | 0.6456 | 3.74 | 0.1049 | -- | 3.15 | 351,011.10 | -26.56 | -31.82 | -30.40 | -36.05 | -- | -- | -253.30 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
| Absci Corp | 5.72m | -110.57m | 596.63m | 155.00 | -- | 2.80 | -- | 104.34 | -1.20 | -1.20 | 0.0621 | 1.89 | 0.0212 | -- | 3.06 | 36,890.32 | -41.08 | -- | -46.22 | -- | -- | -- | -1,933.65 | -- | -- | -93.25 | 0.0467 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
| Olema Pharmaceuticals Inc | 0.00 | -96.66m | 598.85m | 74.00 | -- | 2.32 | -- | -- | -2.16 | -2.16 | 0.00 | 4.62 | 0.00 | -- | -- | 0.00 | -39.24 | -30.06 | -42.54 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| Stoke Therapeutics Inc | 8.78m | -104.70m | 603.27m | 110.00 | -- | 3.37 | -- | 68.70 | -2.38 | -2.38 | 0.1996 | 3.47 | 0.0363 | -- | 26.94 | 79,827.27 | -43.23 | -31.62 | -49.60 | -33.92 | -- | -- | -1,192.34 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
| Lyell Immunopharma Inc | 130.00k | -234.63m | 604.75m | 224.00 | -- | 0.9229 | -- | 4,651.92 | -0.9353 | -0.9353 | 0.0005 | 2.58 | 0.0002 | -- | -- | 580.36 | -27.81 | -- | -29.04 | -- | -- | -- | -180,486.20 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
| SIGA Technologies Inc | 139.92m | 68.07m | 604.99m | 45.00 | 9.05 | 3.07 | 8.81 | 4.32 | 0.9399 | 0.9399 | 1.95 | 2.77 | 0.6227 | 0.3329 | 4.21 | 3,109,272.00 | 30.29 | 22.34 | 36.42 | 27.56 | 87.69 | 88.65 | 48.65 | 41.14 | 3.23 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
| Longboard Pharmaceuticals Inc | 0.00 | -54.42m | 612.48m | 50.00 | -- | 10.18 | -- | -- | -2.39 | -2.39 | 0.00 | 1.67 | 0.00 | -- | -- | 0.00 | -89.72 | -- | -105.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
| Hillevax Inc | 0.00 | -123.57m | 622.75m | 90.00 | -- | 2.25 | -- | -- | -3.04 | -3.04 | 0.00 | 5.57 | 0.00 | -- | -- | 0.00 | -37.35 | -- | -39.90 | -- | -- | -- | -- | -- | -- | -- | 0.0868 | -- | -- | -- | 22.68 | -- | -- | -- |
| Cogent Biosciences Inc | 0.00 | -192.41m | 624.36m | 164.00 | -- | 2.84 | -- | -- | -2.40 | -2.40 | 0.00 | 2.99 | 0.00 | -- | -- | 0.00 | -62.65 | -49.53 | -70.07 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
| Zymeworks Inc | 76.01m | -118.67m | 624.53m | 272.00 | -- | 1.35 | -- | 8.22 | -1.74 | -1.74 | 1.10 | 6.57 | 0.1236 | -- | 2.88 | 279,455.90 | -19.30 | -22.58 | -22.01 | -26.90 | -- | -- | -156.13 | -91.17 | -- | -- | 0.0003 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
Data as of Apr 18 2024. Currency figures normalised to Lyell Immunopharma Inc's reporting currency: US Dollar USD
19.71%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 13.38m | 5.26% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 12.35m | 4.86% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 6.56m | 2.58% |
| Geode Capital Management LLCas of 31 Dec 2023 | 3.94m | 1.55% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 3.54m | 1.39% |
| Citadel Securities LLCas of 31 Dec 2023 | 2.97m | 1.17% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 2.79m | 1.10% |
| MIC Capital Management UK LLPas of 31 Dec 2023 | 1.74m | 0.69% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 1.47m | 0.58% |
| Massachusetts Financial Services Co.as of 31 Dec 2023 | 1.35m | 0.53% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
